ReviewJournal of personalized medicine2022
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Madelyn Burkart et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papertrialcites it
ReviewJournal of personalized medicine2022
Madelyn Burkart et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.